Weiss Multi-Strategy Advisers’s AbbVie ABBV Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25,000	Closed	-$3.83M	–	638
2022 Q2	$3.83M	Buy	+25,000	New	+$3.82M	0.12%	270
2019 Q1	–	Sell	-5,000	Closed	-$461K	–	501
2018 Q4	$461K	Buy	+5,000	New	+$440K	0.02%	358
2015 Q3	–	Sell	-10,000	Closed	-$672K	–	386
2015 Q2	$672K	Buy	+10,000	New	+$653K	0.03%	350

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Weiss Multi-Strategy Advisers's ABBV Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of AbbVie (ABBV) in Q1 2024, closing a stake of 3,723 shares — an estimated $577K sold.

Weiss Multi-Strategy Advisers first reported a position in ABBV in Q4 2013 and held it in 18 quarters. The position peaked at $13.5M in Q4 2022. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

Weiss Multi-Strategy Advisers reported no remaining AbbVie position as of Q1 2024 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 3,723 AbbVie shares in Q1 2024, an estimated $577K.
Weiss Multi-Strategy Advisers first reported a position in AbbVie in Q4 2013 and held it in 18 quarters.
Weiss Multi-Strategy Advisers's AbbVie position peaked at $13.5M in Q4 2022.
3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.